drugset / Trial / NCT02438826

A Study of Galcanezumab in Participants With Chronic Cluster Headache

NCT02438826

Phase 3 Completed 240 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.

Timeline

Start
2015-06-18
Primary completion
2018-03-27
Completion
2019-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Galcanezumab Monoclonal antibody 300 mg Subcutaneous